A Study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation

Europace

Volumn 13, Issue 1, 2011, Pages 31-36

  Fu, Ruibin ^a   Wu, Shulin ^a   Wu, Pingsheng ^b   Qiu, Jian ^c  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

^c Liuhuaqiao Hospital   (China)

Author keywords

Atrial fibrillation; Fibrinogen; Soluble P selectin; von Willebrand factor

Indexed keywords

FIBRINOGEN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PROGNOSIS; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 78650423523     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq346     Document Type: Article

References (37)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-52.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82:2-9N.
3. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990;16:377-80.
4. Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995;76:453-8.
5. Pongratz G, Brandt-Pohlmann M, Henneke KH, Pohle C, Zink D, Gehling G et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation. Chest 1997;111:929-33.
6. Li-Saw-Hee FL, Blann AD, Lip G.Y. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 2000;35: 1926-31.
7. Watson T, Shantsila E, Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-66.
8. Burstein SA, Peng J, Friese P, Wolf RF, Harrison P, Downs T et al. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 1996;14:154-62.
9. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997;29:106-12.
10. Feng D, D'Agostino RB, Silbershatz H, Lipinska I, Massaro J, Levy D et al. Hemostatic State and Atrial Fibrillation (The Framingham Offspring Study). Am J Cardiol 2001;87:168-71.
11. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547-53.
12. Li-Saw-Hee FL, Blann AD, Gurney D, Lip G.Y. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001;22:1741-7.
13. Choudhury A, Chung I, Blann AD, Lip G.Y. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: A comparison of 'healthy control subjects' and 'disease control subjects' in sinus rhythm. J Am Coll Cardiol 2007;49:1957-64.
14. Ferroni P, Basili S, Falco A, Davì G. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid Redox Signal 2004;6:747-56.
15. Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des 2007;13:1661-7.
16. Karásek D, Vaverková H, Halenka M, Slavík L, Novotný D. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. Thromb Res 2009;123:466-75.
17. Balleisen L, Bailey J, Epping PH, Schulte H, van De Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985;54:475-9.
18. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin treatment. Br Heart J 1995;73:527-33.
19. Conway DS, Pearce LA, Chin BS, Hart RG, Lip G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors. Circulation 2002;106:1962-7.
20. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Hang CL et al. Platelet activation in patients with chronic nonvalvular atrial fibrillation. Int Heart J 2006;47:371-9.
21. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 2000;75:227-32.
22. Atrial fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotics therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
23. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183-7.
24. Li-Saw-Hee FL, Blann AD, Edmunds E, Gibbs CR, Lip G.Y. Effect of acute exercise on the raised plasma fibrinogen, soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation. Clin Cardiol 2001;24:409-14.
25. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 2008;51:1790-3.
26. Yuan Z, Bowlin S, Einstadter D, Cebul RD, Conners AR Jr, Rimm AA. Atrial fibrillation as a risk factor for stroke: A retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health 1998;88:395-400.
27. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74.
28. Kamath S, Blann AD, Chin BS, Lanza F, Aleil B, Cazenave JP et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J 2002;23:1788-95.
29. Heeringa J, Conway DS, van Der Kuip DA, Hofman A, Breteler MM, Lip GY et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: The Rotterdam Study 1990-1999. J Thromb Haemost 2006;4: 1944-49.
30. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006;114: E257-354.
31. Singer D, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546-92S.
32. Freestone B, Lip G.Y. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie 2008;28:207-12.
33. Fukuchi M,Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37:1436-42.
34. Lip G.Y. Does atrial fibrillation confer a hypercoagulable statě Lancet 1995;346: 1313-4.
35. Kamath S, Blann AD, Chin BS, Lip G.Y. A prospective randomized trial of aspirin- clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002;40: 484-90.
36. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996;94:425-31.
37. Li-Saw-Hee FL, Blann AD, Lip G.Y. Effects of fixed low-dose warfarin, aspirinwarfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000;31:828-33.